查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球脱髮药物市场 - 2022-2029
市场调查报告书
商品编码
1140714

全球脱髮药物市场 - 2022-2029

Global Alopecia Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

脱髮治疗市场预计将在 2021 年达到 82.4 亿美元，到 2029 年达到 148 亿美元，在预测期间(2022-2029 年)以 8.0% 的复合年增长率增长。

脱髮是指部分或全部毛髮脱落，尤其是头皮、整个头部或全身毛髮。分为斑秃、男性型秃髮、斑秃、牵引性秃髮、斑秃、斑秃等类型。它可能是由遗传、荷尔蒙变化、医疗状况或衰老的正常部分引起的。药物、头髮移植和激光治疗用于治疗脱髮。

市场动态

脱髮治疗市场 慢性疾病如急性应激障碍、多囊卵巢疾病 (pcod)、甲状腺机能亢进、甲状腺机能减退、癌症、狼疮、垂体功能减退症的患病率越来越高 背景是我们正在做的事情。

脱髮患病率的增加和脱髮治疗研发活动的增加预计将推动市场增长

随着烟草和酒精消费量增加导致脱髮患病率增加，市场对脱髮治疗的需求不断增加。有几个因素会导致脱髮，包括衰老和荷尔蒙失调。急性应激障碍、多囊卵巢病 (PCOD)、甲状腺功能亢进、甲状腺功能减退、癌症、狼疮、垂体功能减退等慢性疾病的患病率增加似乎将刺激市场增长。

针对脱髮治疗药物的研发活动正在加紧。预计新疗法的批准将刺激市场增长。例如，2020 年 7 月，Concert Pharmaceuticals, Inc. 的口服 Janus 激□抑製剂 CTP-543 获得了突破性治疗指定，用于治疗成人中重度斑秃患者。该临床试验表明，CTP-543可用于中度至重度斑秃患者。患者接受 CTP-543 8 mg 每天两次或 12 mg 每天两次。 CTP-543 与安慰剂相比，在第 24 周根据脱髮严重程度工具 (SALT) 测量的基线相对变化□50% 的患者中显示出统计学上的显着差异，主要达到了评估项目。 CTP-543 一般耐受性良好。患者中仅报告了 1 起严重的不良事件。

2020 年 3 月，礼来公司获得了美国食品药品监督管理局 (FDA) 授予的用于治疗斑秃的巴瑞替尼的突破性疗法认定。 Baricitinib 是一种每日一次的口服 JAK 抑製剂。 varicitinib 在斑秃患者中的 II 期临床试验显示没有严重的不良事件，也没有新的安全信号。此外，仅观察到轻度或中度治疗不良事件。

多个组织、团体和研究机构参与了对脱髮管理和治疗的研究。例如，国家斑秃基金会 (NAAF) 是一个致力于提高人们对斑秃的认识的非营利组织。 NAAF 支持研究以寻找治疗斑秃的治疗方法和可接受的治疗方法，支持患有该疾病的患者，并对公众进行有关斑秃的教育。该组织提供支持、意识和宣传、研究以寻找治疗或治愈斑秃的方法。

轻微和严重的药物副作用阻碍市场增长

2020年，根据以临床为中心的药学刊物American Pharmacists，他们发表了一篇文章——雄激素性脱髮的治疗选择，用于治疗雄激素性脱髮的药物有很多副作用。例如，局部使用米诺地尔可引起局部红斑和瘙痒，以及水肿(肿胀)、面部毛髮过度生长、头髮变色、心动过速和乳房疼痛等副作用。口服非那雄胺可引起头晕和体位性低血压。这些是市场增长的主要障碍。

行业分析

全球脱髮治疗市场根据波特五力、监管分析、供应链分析和定价分析、报销分析和未满足的需求等各种行业因素对市场进行了深入分析。

细分分析

预计斑秃细分市场将占据全球脱髮治疗市场最大的市场份额

由于斑秃的高患病率，斑秃细分市场占有率最高。根据美国斑秃协会的数据，全世界约有 1.47 亿人患有斑秃。斑秃表现为头皮上离散的、光滑的脱髮斑块。它也可能发生在其他有头髮的区域，例如眉毛、睫毛、鬍鬚和四肢。斑秃常见于自身免疫性疾病患者，即唐氏综合症、糖尿病和甲状腺功能亢进症患者。斑秃也可发展为普秃或全秃。几家公司专注于开发治疗斑秃的疗法。作为斑秃的治疗方法，存在一条有希望的管道。例如，2019 年 1 月，辉瑞日本公司开始了其口服 JAK3 抑製剂 PF-06651600 的 2/3 期试验，用于治疗中度至重度斑秃患者。

按地区分析

北美在全球脱髮药物市场中占有最大的市场份额。

由于脱髮的高患病率，北美在脱髮药物市场占据主导地位。根据全国斑秃的数据，美国约有 680 万人患有斑秃。根据美国脱髮协会的数据，大约 95% 的男性脱髮是由男性型脱髮引起的。一些公共和私营公司正在为治疗脱髮的新疗法的研发活动筹集资金。正在进行技术创新以开发治疗脱髮的疗法。急性应激障碍、多囊卵巢病 (pcod)、甲状腺功能亢进、甲状腺功能减退、癌症、狼疮和垂体功能减退症的高患病率预计将刺激市场增长。

竞争格局

由于存在多个国际和区域参与者，脱髮治疗市场是一个竞争激烈的市场。疾病多样化、技术进步、收入获取和机会正在加剧市场竞争。 Aclaris Therapeutics, Cipla, Concert Pharmaceuticals, Daiichi Sankyo, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Company, Sun Pharmaceutical Industries 等等。 Inc.、Sun Pharmaceuticals Industries Ltd. 是市场份额较大的主要参与者。

公司利用产品开发、研发、技术进步和市场扩张战略来维持其市场地位。例如，2020 年 6 月，Follica, Inc. 宣布已成功完成治疗男性型脱髮男性脱髮的安全性和有效性优化研究，并准备将其主导项目推进到 III 期开发。正在进行中，并在与美国食品和药物管理局 (FDA) 的会议上收到了积极的反馈。

  • 2019 年 12 月，Follica, Inc. 公布了一项针对治疗男性型脱髮的安全性和有效性优化研究的主要结果。该研究旨在选择结合 Follica 专有设备和外用药物的最佳治疗方案，成功实现了其主要终点。与治疗 3 个月后的基线相比，这种治疗显示可见毛髮数量有统计学意义的 44% 改善。此外，与基线相比，治疗 3 个月后可见毛髮数量的总体改善为 29%，表明最佳治疗方案的结果显着改善。
  • 2021 年 8 月，开发免疫炎性疾病新候选药物的临床阶段生物製药公司 Aclaris Therapeutics, Inc. 与礼来 (Eli Lilly) 公司签订了治疗斑秃的非独家专利许可协议。宣布它已将 Aclaris 许可的与使用礼来公司的 JAK 抑製剂 varicitinib 相关的专利的某些权利转让给礼来公司。

值得关注的重点公司

Aclaris 治疗公司：

概述 Aclaris 疗法是一家临床阶段的生物製药公司，正在开发一系列新型皮肤病学和免疫炎症疗法。成立于2009年，总部位于美国宾夕法尼亚州。

产品组合

XELJANZ：一种口服药物，可在标籤外开具治疗斑秃的处方。也称为託法替尼。它未经 FDA 批准可用于治疗头髮稀疏。

重大进展。 2022 年 8 月，Aclaris 宣布与礼来(Lilly)就斑秃达成专利许可协议。

全球脱髮治疗市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页内容。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 脱髮患者增加
      • 启动脱髮治疗的研发活动
    • 限制因素
      • 轻微和严重的药物副作用
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 监管分析
  • 供应链分析
  • 定价分析
  • 保险报销分析
  • 未满足的需求分析

第6章按疾病类型

  • 男性型秃髮
  • 斑秃
  • 瘢痕性脱髮
  • 牵引性脱髮
  • 全身脱髮
  • 原发性脱髮
  • 其他

第 7 章性别

  • 男
  • 女性

第 8 章按药物类型

  • 外部代理
    • 米诺地尔
    • 非那雄胺
  • 肾上腺皮质类固醇
  • 免疫抑製剂
    • 环孢素
  • 其他

第 9 章给药途径

  • 口语
  • 外用
  • 注入

第十章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 13 章公司简介

  • Aclaris Therapeutics Inc.
    • 公司概况
    • 表格组合和说明
    • 主要亮点
    • 财务摘要
  • Cipla Inc.
  • Concert Pharmaceuticals Inc
  • Daiichi Sankyo Inc
  • GlaxoSmithKline PLC
  • HCell Inc.
  • Johnson & Johnson
  • Merck & Co. Inc
  • Sun Pharmaceuticals Industries Ltd
  • Lexington Intl., LLC

第14章 全球脱髮治疗市场-DataM

简介目录
Product Code: DMPH2578

Market Overview

Alopecia Treatment Market was valued US$ 8.24 billion in 2021 and is estimated to reach US$ 14.8 billion by 2029, growing at a CAGR of 8.0% during the forecast period (2022-2029).

Alopecia is the partial or complete loss of hair, especially on the scalp, entire head, or the entire body. It is classified into different types as the alopecia areata, androgenic alopecia, alopecia totalis, traction alopecia, alopecia Universalis, and cicatricial alopecia. It occurred due to heredity, hormonal changes, medical conditions, or a normal part of aging. Drugs, hair transplants, and laser therapy are used for the treatment of Alopecia.

Market Dynamics

The alopecia treatment market is driven by the growing prevalence of chronic diseases, such as acute stress disorder, polycystic ovary disease (pcod), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism.

Increasing prevalence of alopecia and rising R&D activities for alopecia therapy are expected to drive market growth

The market is driven by the increasing demand for alopecia treatment with the increasing prevalence of alopecia due to the increasing consumption of tobacco and alcohol. Several factors, such as aging and hormonal anomalies, lead to the development of Alopecia. The growing prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism, shall stimulate market growth.

There is increasing research and development activities for the development of Alopecia therapies. The expected approval of emerging therapies shall stimulate market growth. For instance, in July 2020, Concert Pharmaceuticals, Inc. had received the Breakthrough Therapy Designation for the oral Janus kinase inhibitor, CTP-543, to treat adult patients with moderate-to-severe alopecia areata. The clinical trial has demonstrated that the use of the CTP-543 among patients with moderate-to-severe alopecia areata. The patients were treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543. CTP-543 has met the primary efficacy endpoint with statistically significant differences relative to placebo in the patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by the Severity of Alopecia Tool (SALT). CTP-543 was generally well tolerated. Only one serious adverse event was reported among the patients.

In March 2020, Eli Lilly had received the breakthrough therapy designation from the United Food and Drug Administration (FDA) for baricitinib to treat alopecia areata. Baricitinib is the once-daily oral JAK inhibitor. The Phase II trial of the baricitinib conducted among the patients with the alopecia areata demonstrated no new safety signals with no serious adverse events. Only mild or moderate treatment-emergent adverse events (TEAEs) were observed among the patients.

Several organizations, associations, and institutes are involved in researching the management and treatment of alopecia. For instance, The National Alopecia Areata Foundation (NAAF) is a non-profit organization involved in raising awareness regarding the alopecia areata. NAAF supports research to find a cure or acceptable treatment for alopecia areata, supports those with the disease, and educates the public about alopecia areata. This organization provides support, awareness & advocacy, and research to find a treatment or cure for alopecia.

Minor & Major side effects of drugs is likely to hinder the market growth

According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2020 that medication used for the treatment of androgenetic alopecia has many side effects. For example, topical minoxidil can cause local erythema and pruritus and also some side effects like Edema (swelling), excessive hair growth on face, hair discoloration, tachycardia, breast pain. Oral drug finasteride can cause dizziness, orthostatic hypotension and others. These are the major restricting factors of the market growth.

Industry Analysis

The global alopecia treatment market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis and pricing analysis, reimbursement analysis, unmet needs.

Segment Analysis

Alopecia areata segment is expected to hold the largest market share in global alopecia treatment market

The alopecia areata segment accounts for the highest market due to the high prevalence of alopecia areata. According to the National Alopecia Areata, approximately 147 million people are affected by alopecia areata worldwide. Alopecia areata is presented with discrete, smooth patches of alopecia on the scalp. It also occurs in other hair-bearing areas, such as the eyebrows, eyelashes, beard, and extremities. Alopecia areata is prevalent among patients with autoimmune diseases, i.e., Down's syndrome, diabetes, and hyperthyroidism. It can progress into the alopecia Universalis and totalis. Several companies are focusing on developing therapies for the treatment of Alopecia Areata. There is the presence of a promising pipeline for the treatment of Alopecia Areata. For instance, in January 2019, Pfizer Inc. had initiated the Phase II/III trial of oral JAK3 inhibitor, PF-06651600, to treat patients with moderate to severe alopecia areata.

Geographical Analysis

North America region holds the largest market share in the global alopecia treatment market

North America dominated the alopecia treatment market due to the high prevalence of alopecia. According to the National Alopecia Areata, approximately 6.8 million people are affected by alopecia areata in the United States. According to the American Hair Loss Association, approximately 95% of hair loss occurred due to androgenetic alopecia among men. Several public and private companies raise the investment for the research and development activities for the novel therapies to treat alopecia. There is growing innovation for the development of therapies for the treatment of alopecia. The high prevalence of acute stress disorder, polycystic ovary disease (pcod), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism shall stimulate market growth.

Competitive Landscape

The alopecia treatment market is highly competitive with the presence of several international and local market players. Disease diversification, technological advancement, revenue generation, and opportunities intensify the market competition. Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., and Sun Pharmaceuticals Industries Ltd are the leading market players with significant market share.

Companies are using product development, research and development, technology advancement, and market expansion strategies for holding their position in the market. For instance, in June 2020, Follica, Inc. had received positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase III development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

  • In December 2019, Follica, Inc. had announced the topline results from its safety and efficacy optimization study to treat hair loss in male androgenetic alopecia. The study was designed to select the optimal treatment regimen using Follica's proprietary device combined with a topical drug and successfully met its primary endpoint. The treatment regimen demonstrated a statistically significant 44% improvement of visible hair count after three months of treatment compared to baseline. The overall improvement of visible hair count after three months of treatment was 29% compared to baseline, and a substantially improved outcome was seen with the optimal treatment regimen.
  • In Aug 2021, Aclaris Therapeutics, Inc. a clinical-stage biopharma company that develops new drug candidates for immuno-inflammatory diseases, announced its non-exclusive patent license agreement with Eli Lilly and Company by which Aclaris gave some rights to Lilly under patents that Aclaris licences for usage of JAK inhibitor of Lilly baricitinib for Alopecia areata treatment.

Key Companies to Watch

Aclaris therapeutics Inc:

Overview: Aclaris therapeutics is clinical stage biopharma company that develops novel dermatological therapies and pipeline of drugs for immune-inflammatory diseases. It was founded in 2009 and is headquartered in Pennsylvania, United States.

Product Portfolio:

XELJANZ: It is the oral medicine that can be prescribes off label for alopecia areata treatment. It is also known as Tofacitinib. It is not FDA approved medicine for hair loss.

Key Developments: In Aug 2022, Aclaris announced its patent licence agreement for alopecia areata with Lilly.

The global alopecia treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Increasing prevalence of alopecia
      • 4.1.1.2. Rising R&D activities for alopecia therapies
    • 4.1.2. Restraints:
      • 4.1.2.1. Minor & Major side effects of drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Regulatory Analysis
  • 5.3 Supply Chain Analysis
  • 5.4 Pricing Analysis
  • 5.5 Reimbursement Analysis
  • 5.6 Unmet Needs

6. By Disease Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 6.1.2. Market Attractiveness Index, By Disease Type
  • 6.2. Androgenic Alopecia
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, USD Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. Alopecia Areata
  • 6.4. Cicatricial Alopecia
  • 6.5. Traction Alopecia
  • 6.6. Alopecia Totalis
  • 6.7. Alopecia Universalis
  • 6.8. Others

7. By Gender

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 7.1.2. Market Attractiveness Index, By Gender
  • 7.2. Male
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Female

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 8.1.2. Market Attractiveness Index, By Gender
  • 8.2. Topical Agents
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Minoxidil
    • 8.2.4. Finasteride
  • 8.3. Corticosteroids
  • 8.4. Immunosuppressants
    • 8.4.1. Cyclosporine
  • 8.5. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Topical
  • 9.4. Injectable

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, USD Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. The U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. The U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. Australia
      • 11.5.8.5. Rest of Asia Pacific
  • 11.6. The Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Aclaris Therapeutics Inc
    • 13.1.1. Company Overview
    • 13.1.2. Form Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Cipla Inc.
  • 13.3. Concert Pharmaceuticals Inc
  • 13.4. Daiichi Sankyo Inc
  • 13.5. GlaxoSmithKline PLC
  • 13.6. HCell Inc.
  • 13.7. Johnson & Johnson
  • 13.8. Merck & Co. Inc
  • 13.9. Sun Pharmaceuticals Industries Ltd
  • 13.10. Lexington Intl., LLC

LIST NOT EXHAUSTIVE

14. Global Alopecia Treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Method of Fixation
  • 14.3. Contact Us